Related Experiment Video

Updated: Apr 24, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

14.4K

Anti-inflammatory and anti-thrombogenic effects of atorvastatin in acute ischemic stroke

Lianqiu Min1, Shuai Shao2, Xiaoning Wu1

  • 1Department of Neurology, First Affiliated Hospital of Liaoning Medical University, Jinzhou 121001, Liaoning Province, China.

Neural Regeneration Research
|September 11, 2014
PubMed

Insights

Atorvastatin significantly reduced inflammation and thrombogenesis in acute ischemic stroke patients. These beneficial effects occurred independently of atorvastatin's lipid-lowering actions.

Area of Science:

  • Cardiovascular Medicine
  • Neuroscience
  • Pharmacology

Background:

  • Carotid artery plaque is associated with inflammation and thrombogenesis.
  • Atorvastatin is commonly used for lipid reduction, but its non-lipid effects require further clarification.
  • The anti-inflammatory and anti-thrombogenic roles of atorvastatin in acute ischemic stroke patients with large-artery atherosclerosis are not fully understood.

Purpose of the Study:

  • To investigate the effects of atorvastatin on inflammation and thrombogenesis in patients with acute ischemic stroke due to large-artery atherosclerosis.
  • To determine if these effects are independent of lipid-lowering properties.

Main Methods:

  • Eighty-nine patients with acute ischemic stroke from large-artery atherosclerosis were randomized into two groups.
  • The study group received atorvastatin 20 mg/day, while the control group received a placebo.
  • Both groups received standard care, including antiplatelet therapy.

Main Results:

  • After 4 weeks, the study group showed significantly lower levels of C-reactive protein, fibrinogen, and D-dimer compared to the control group.
  • These reductions in inflammatory and thrombotic markers were not correlated with changes in triacylglycerol or low-density lipoprotein cholesterol levels.
  • Atorvastatin demonstrated significant anti-inflammatory and anti-thrombogenic effects.

Conclusions:

  • Atorvastatin effectively reduces inflammation and thrombogenesis in patients with acute ischemic stroke caused by large-artery atherosclerosis.
  • These beneficial effects are independent of atorvastatin's lipid-lowering capabilities.
  • Atorvastatin may offer therapeutic benefits beyond cholesterol management in this patient population.

Keywords:
C-reactive proteinD-dimeratorvastatinbrain injuryfibrinogengrants-supported paperinflammationischemic strokelarge-artery atherosclerosislow-density lipo-protein cholesterolneural regenerationneuroregenerationthrombustriacylglycerol

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.2K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

27.4K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
634
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
481
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
442